OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
September 03, 2022
It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.
August 31, 2022
Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.
Pharmaceutical Technology spoke with Andrew Anderson, Global Head Strategic Account Management and Mary Todas, Director Technical Development and Regulatory Affairs, both with Pfizer CentreOne, about best practices for API quality.
August 30, 2022
Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.
August 22, 2022
ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.
August 16, 2022
In this episode of the Drug Solutions Podcast, John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals shares outsourcing strategies in biopharma.
August 12, 2022
Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.
August 09, 2022
Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).
August 04, 2022
Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.
August 03, 2022
This article reviews sources of excipient variability, including raw materials and processing, both of which may vary from supplier to supplier and from plant to plant for a single manufacturer.